Da traduttori professionisti, imprese, pagine web e archivi di traduzione disponibili gratuitamente al pubblico.
adjunctive treatment in patients at risk of methotrexate toxicity
adjunctive treatment in patients at risk of methotrexate
titre du document points to consider on the need for assessment of reproductive toxicity of human insulin analogues
titel på dokumentet points to consider on the need for assessment of reproductive toxicity of human insulin analogues
concept paper on the development of a cpmp points to consider on the need for reproduction toxicity studies in the development of human insulin analogues adoptée en décembre 2000
sendt til høring i december 2000
"risks of environmental dioxins: linking epidemiology with toxicity studies to strengthen accurate risk assessment", février 2000
"risks of environmental dioxins: linking epidemiology with toxicity studies to strengthen accurate risk assessment", februar 2000
un cas d'évolution fatale était associé à une thrombocytopénie de grade 4 selon le common toxicity criteria (ctc).
et tilfælde var letalt og var forbundet med trombocytopeni common toxicity criteria (ctc) grad 4.
taux de plaquettes ≥ 100 x 109/l toxicité non hématologique selon la classification « common toxicity criteria » (ctc)
trombocyttal ≥ 100 x 109/l almindelige toksicitetskriterier (ctc, common toxicity criteria) for ikke-hæmatologisk toksicitet
pre-approval information for registration of new medicinal products for food producing animals with respect to antimicrobial resistance injection site residues user safety estimation of predicted environmental concentrations, including harmonisation of default values and development of a harmonised computer model toxicity of substances to dung fauna degradation of substances in manure
estimation of predicted environmental concentrations, including harmonisation of default values and development of a harmonised computer model toxicity of substances to dung fauna degradation of substances in manure
environ 8 % des patients ont développé un effet indésirable sévère (common toxicity criteria (ctc), grade 3 ou 4).
cirka 8 % af patienterne havde en alvorlig bivirkning (common toxicity criteria, (ctc), grad 3 eller 4).
les événements indésirables survenus plus fréquemment (≥ 3%) dans le groupe tarceva que dans le groupe placebo dans l’étude pivot br.21 et chez au moins 10% des patients du groupe tarceva sont résumés par grade nci-ctc (national cancer institute-common toxicity criteria) dans le tableau 1.
de bivirkninger, som i det pivotale studie br. 21 optrådte hyppigere (≥3%) hos tarceva- behandlede patienter end hos patienter, som fik placebo, og som optrådte hos mindst 10% af patienterne i tarceva- gruppen, er sammenfattet i henhold til national cancer institute- common toxicity criteria (nci- ctc) grade i tabel 1.